nejm semaglutide cardiovascular and Outcomes in Patients with Type 2 Diabetes Semaglutide and cardiovascular outcomes by

GLP-1 medications like Wegovy, Zepbound, and compounded alternatives are increasingly being used to lose the last 5 to 10 pounds. But is that goal worth the long-term commitment these medications often require

The aim of this review is to provide an in-depth summary of CVOT datacrystallising the key findings, from safety to efficacyand to offer a practical perspective for physicians

As the first Canadianbased pharmaceutical company to gain authorization for a generic equivalent of Ozempic, this approval reinforces Apotex's leadership in bringing highquality, affordable alternatives to Canadians and reflects the our longstanding commitment to strengthening access to medicines across the country

Significantly delays gastric emptying and structurally targets food center triggers in the brain, helping you naturally transition away from emotional eating or intense sugar cravings

Glucagon-like peptide-1 (GLP-1) mimetics are a class of recently developed diabetes therapy that do not lead to hypoglycemic, but some reports have suggested a relationship between GLP-1 mimetics and ketogenesis

Recent advances in the generation, purification and cellular delivery of RNA have enabled development of RNA-based therapeutics for a broad array of applicat...